List view / Grid view
Researchers have developed an easy-to-use method for measuring leg dystonia in children with cerebral palsy – allowing doctors to personalise treatments more effectively.
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
Researchers at UNSW Sydney have unveiled a next-generation CRISPR tool that could lead to safer treatments for genetic disorders, including Sickle Cell.
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…
An existing asthma drug has been shown to almost completely prevent life-threatening allergic reactions to food in mice, after researchers found a previously unknown genetic pathway linked to anaphylaxis.
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant “zombie” tumour cells – which could allow for the development of more durable treatments.
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma's productivity crisis – and why it will take longer than the optimists claim.
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
Researchers at Florida A&M University have identified a new compound – NSL-YHJ-2-27 – that disrupts key survival pathways in aromatase inhibitor-resistant breast cancer cells – offering a potential new treatment for hard-to-treat cases.
Scientists in China have used 3D bioprinting to grow kidney tumours from patients’ own cells, creating realistic models that could speed up development of personalised treatments.
New research from Harvard Medical School shows that natural lithium deficiency in the brain may be a key early factor driving Alzheimer’s disease – which allow for the development of new approaches to preventing and reversing cognitive decline.
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
